Nexgel Inc Stock Price, News & Analysis

NEXGEL (NASDAQ: NXGL) announced that CEO Adam Levy will present at the LD Micro Main Event XIX conference in San Diego on October 20, 2025 at 11:30 a.m. PT. The presentation takes place at the Hotel Del Coronado in Track 4 and will be available via webcast.

Investors can access the live webcast at https://ir.nexgel.com/news-events/events-presentations. To request a one-on-one meeting with Mr. Levy during the event, contact KCSA Strategic Communications at Nexgel@KCSA.com.

NEXGEL (NASDAQ: NXGL) reported strong Q2 2025 financial results with revenue reaching $2.88 million, marking a significant 100.3% increase year-over-year. The company achieved substantial margin improvement with gross profit margin expanding to 43.6% from 20.3% in Q2 2024.

Key highlights include a reduced net loss of $0.67 million (vs. $0.89 million in Q2 2024) and improved Adjusted EBITDA of ($0.42) million. Post-quarter, NEXGEL secured a $1 million non-dilutive advance from STADA and raised $1.05 million in additional financing. The company maintains its 2025 guidance of $13 million in revenue and expects to achieve positive EBITDA during the year.

NEXGEL (NASDAQ: NXGL), a provider of ultra-gentle hydrogel products for healthcare and consumer applications, will release its Q2 2025 financial results on August 12, 2025, after market close.

The company will host a conference call at 4:30 P.M. ET on the same day. Investors can join via phone at 1-800-274-8461 (U.S.) or 1-203-518-9814 (International). A replay will be available through August 26, 2025, and the webcast will be archived for 90 days.

NEXGEL (NASDAQ: NXGL), a provider of medical and OTC hydrogel products, has appointed Steve Ciardiello, CPA, to its Board of Directors. As the current Chief Accounting Officer of Shutterstock (NYSE: SSTK), Ciardiello brings over 25 years of senior finance executive experience.

Ciardiello's expertise includes financial leadership, strategic execution, and corporate governance in high-growth public companies. At Shutterstock, he leads a global finance team managing SEC reporting, tax, internal audit, and general accounting. His background includes implementing financial transformation initiatives and over 15 years of Big 4 public accounting experience.

NEXGEL (NASDAQ: NXGL), a provider of medical and OTC hydrogel products, has announced a $950,000 registered direct offering at $2.30 per share, issuing 413,044 shares of common stock. The company is also conducting a concurrent private placement of unregistered warrants to purchase up to 206,522 shares at an exercise price of $4.25 per share.

The warrants will be exercisable immediately upon issuance with a five-year term. This financing, combined with their current cash position and a recent $1 million non-dilutive advance from STADA, aims to strengthen NEXGEL's balance sheet as they prepare for anticipated growth in the second half of the year. Alere Financial Partners, LLC served as the exclusive placement agent for the offering.

NEXGEL (NASDAQ: NXGL), a provider of medical and OTC hydrogel products, announced its CEO Adam Levy will participate in the 6th Annual CEO Networking Event hosted by Semco Capital. The event will take place on June 2, 2025 in Chicago, featuring a fireside chat with Scott Weis.

The networking event brings together microcap companies with strong management teams and growth potential. Interested investors can contact Scott Weis for attendance information.

NEXGEL (NASDAQ:NXGL), a hydrogel products manufacturer, has expanded its partnership with STADA Arzneimittel AG for the North American market. The collaboration focuses on launching digestive enzyme formulas and solutions for scars and stretch marks.

As part of this strategic expansion, STADA will provide $1 million in non-dilutive capital to support NEXGEL's product launches and marketing initiatives. The partnership aims to bring innovative health solutions to North American consumers, leveraging NEXGEL's expertise in high-water-content hydrogel products and STADA's position as a European consumer health leader.

NEXGEL (NASDAQ: NXGL) reported strong Q1 2025 financial results with revenue of $2.81 million, marking a 121% increase from Q1 2024's $1.27 million. The company's gross profit margin improved significantly to 42.4% from 12.6% in Q1 2024. Despite showing improved metrics, NEXGEL recorded a net loss of $0.71 million, though reduced from $0.85 million in Q1 2024. The company's EBITDA loss narrowed to ($0.54) million from ($0.84) million year-over-year. CEO Adam Levy expressed confidence in meeting the company's 2025 guidance of $13 million in revenue and achieving positive EBITDA during the year, citing growth opportunities in contract manufacturing with clients like Cintas and upcoming consumer branded product launches.

NEXGEL (NASDAQ: NXGL), a provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, has scheduled its first quarter 2025 financial results announcement for May 13, 2025, after market close.

The company will host a conference call at 4:30 P.M. ET on the same day. Interested participants can join via phone (U.S. Toll Free: 1-800-343-4849 or International: 1-203-518-9848) or webcast. A replay will be available through May 27, 2025, accessible by dialing +1-844-512-2921 (U.S.) or +1-412-317-6671 (International) with code 11159118. The webcast recording will be available for 90 days.